

[View this email in your browser](#)



## Randomized Trial to Prevent Vascular Events in HIV

### September 2023 Table of Contents

- [Trial Status: We Achieved 100% of Participants Off Study!](#)
- [REPRIEVE Community Forums in September](#)
- [Study Closure Reminders and FAQ](#)
- [REPRIEVE Feature in The New York Times](#)
- [NEJM Podcast: Preventing HIV's Collateral Cardiovascular Damage](#)
- [August 2023 MOB Newsletter](#)
- [Join Us for the Next Team/Site Call Tuesday September 19th](#)
- [Are You Up to Date?](#)



### **Trial Status: We Achieved 100% of Participants Off Study!**

*We are happy to share that thanks to an incredible effort by each and every site team, 100% of participants are now off-study!!!*

*REPRIEVE Leadership recognizes this incredible accomplishment, and is incredibly appreciative of the hard work put in by EVERYONE to achieve this milestone!!!*

**Please Promote REPRIEVE  
Community Forums**



# REPRIEVE COMMUNITY FORUM



Mark your calendars! REPRIEVE will be hosting two community forums to review the trial results.

These will be held on Thursday, September 21st at 1:00 PM ET (English) and Friday, September 29th at 11:00 AM ET (Spanish).

Please share information about these important events with REPRIEVE participants, and anyone else you think would be interested in joining!

For more information, visit the REPRIEVE website: <https://www.reprievetrial.org/for-participants/community-forum/>.

## Study Closure Reminders and FAQ



**Shipping Deadline:** All specimens from site labs are to be sent to BRI by September 18th, 2023.

If you are at a non-ACTG site in the US or Canada and need a shipping label, please email [mghreprieveshipping@partners.org](mailto:mghreprieveshipping@partners.org)

**Query Response Deadline:** The deadline for site responses and corrections is October 16th 2023.

[Click here](#) to download slides the REPRIEVE Data Managers developed on this topic.

OpenClinica A5332 REPRIEVE (A5332) | Change Site ID

Home | Subject Matrix | **Notes & Discrepancies** | Study Audit Log | Tasks

1. Click Notes & Discrepancies

Subject Matrix for A5332 REPRIEVE

Study Subject ID	Screening	Entry	Month 1	Month 4	Month 8	Month 12	Month 16	Month 20
10001000								
10001012								
10001013								
10001014								
10001015								
10001016								
10001017								
10001018								
10001019								
100020								

Or go to the FSTRF YouTube channel to access an instructional video [here](#)



**Q.** When can I deregister the REPRIEVE (A5332) protocol with DAIDS protocol registration?

**A.** The REPRIEVE study closure SOP indicates that deregistration of the protocol with DAIDS protocol registration is to occur *after* confirmation of study closure with the site's IRB/EC (January 1, 2024). Study closure with the site's IRB/EC is to be completed after unblinding (November 20th, 2023).



We are so excited to share two recent media showcasing REPRIEVE!

## The New York Times

### For 'Silver Tsunami' With H.I.V., New Hope for Healthy Aging

A recent study showed that a statin drug significantly lowered the risk of heart attacks and strokes among middle-aged and older people with the virus.

"This is really an important study," said Dr. Anthony S. Fauci, who as the former director of the National Institute of Allergy and Infectious Diseases — he retired in December — was among the N.I.H.'s leaders who approved Reprieve's mammoth budget. "The results, in some respects — they're even better than I would have expected."

On September 10th, The New York Times featured REPRIEVE as part of the new hope for people aging with HIV. The article includes quotes from Dr. Anthony Fauci and REPRIEVE Co-PI Dr. Steven Grinspoon! [Click here](#) to access the article.



The NEW ENGLAND  
JOURNAL of MEDICINE

## NEJM Podcast: Preventing HIV's Collateral Cardiovascular Damage

The New England Journal of Medicine's Intention to Treat series recently reviewed the results of REPRIEVE!

[Click here](#) to listen to interviews with REPRIEVE Co-PI Dr. Steven Grinspoon and two individuals with HIV as they discuss the meaning of REPRIEVE's results for PWH.

Please share these links with REPRIEVE participants, clinicians, and the HIV community in your area.

For more news updates, please refer to the REPRIEVE website:  
<https://www.reprievetrial.org/learnmore/news/>.



## August 2023 MOB Newsletter

The Office of Clinical Site Oversight has asked us to share the August 2023 20th edition of the OCSO MOB Newsletter! You can read the newsletter by clicking the link [here](#).



## Join Us for the Next Team/Site Call Tuesday September 19th

If you have any questions in advance of the site call we'd love to hear from you!  
Please email them to [Katie Fitch](#) at the REPRIEVE CCC.

***Note that REPRIEVE will continue to hold monthly site calls during study closure to share important updates and answer any questions sites may have.***

12:00 PM PERU (PET)  
1:00 PM US (EDT)  
1:00 PM HAITI (EDT)  
1:00 PM PUERTO RICO (AST)

2:00 PM BRAZIL (BRT)  
7:00 PM BOTSWANA (CAT)\*\*\*  
7:00 PM SOUTH AFRICA (SAST)\*\*\*  
7:00 PM ZIMBABWE (CAT)\*\*\*  
8:00 PM UGANDA (EAT)\*\*\*  
10:30 PM INDIA (IST)\*\*\*

12:00 AM (May 17th 2023) THAILAND (ICT)\*\*\*

\*\*\*We do not expect site staff to join these calls during their off-work hours. Instead, we will post slides from this call on the A5332 PSWP.

Remember that questions are always welcome at [actg.corea5332@fstrf.org](mailto:actg.corea5332@fstrf.org)

## **REPRIEVE (A5332): Are You Up to Date?**

**For A5332 please use:**

*Protocol Version 6.0 dated 05/16/2022*

*MOPS Version 6.0 dated 12/14/2022*

*LPC for ACTG Sites Version 6.0 dated 06/03/2022*

*LPC for Non-ACTG Sites Version 6.0 dated 09/08/2022*

*FAQs dated 09/02/2022*

*Coenrollment Guidelines dated 02/06/2023*

*These documents are on the [A5332 PSWP](#)*

***For future reference, all newsletters are available on the  
REPRIEVE Website***

*We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at [reprieve.news@fstrf.org](mailto:reprieve.news@fstrf.org).*



**Like, comment, share, and retweet!**

### **REPRIEVE Trial Clinical Coordinating Center**

Massachusetts General Hospital  
55 Fruit Street, 5LON 207  
Boston, MA USA 02114

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#).

---

This email was sent to [mdiggs@mgh.harvard.edu](mailto:mdiggs@mgh.harvard.edu)  
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)  
Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

